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Abstract
Huntington’s disease (HD) is an autosomal dominant progressive neurodegenerative disorder caused by an expansion of
a CAG/polyglutamine repeat for which there are no disease modifying treatments. In recent years, transcriptional
dysregulation has emerged as a pathogenic process that appears early in disease progression and has been recapitulated
across multiple HD models. Altered histone acetylation has been proposed to underlie this transcriptional dysregulation
and histone deacetylase (HDAC) inhibitors, such as suberoylanilide hydroxamic acid (SAHA), have been shown to
improve polyglutamine-dependent phenotypes in numerous HD models. However potent pan-HDAC inhibitors such as
SAHA display toxic side-effects. To better understand the mechanism underlying this potential therapeutic benefit and to
dissociate the beneficial and toxic effects of SAHA, we set out to identify the specific HDAC(s) involved in this process.
For this purpose, we are exploring the effect of the genetic reduction of specific HDACs on HD-related phenotypes in the
R6/2 mouse model of HD. The study presented here focuses on HDAC3, which, as a class I HDAC, is one of the preferred
targets of SAHA and is directly involved in histone deacetylation. To evaluate a potential benefit of Hdac3 genetic
reduction in R6/2, we generated a mouse carrying a critical deletion in the Hdac3 gene. We confirmed that the complete
knock-out of Hdac3 is embryonic lethal. To test the effects of HDAC3 inhibition, we used Hdac3
+/2 heterozygotes to
reduce nuclear HDAC3 levels in R6/2 mice. We found that Hdac3 knock-down does not ameliorate physiological or
behavioural phenotypes and has no effect on molecular changes including dysregulated transcripts. We conclude that
HDAC3 should not be considered as the major mediator of the beneficial effect induced by SAHA and other HDAC
inhibitors in HD.
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Introduction
Huntington’s disease (HD) is an autosomal dominant progres-
sive neurodegenerative disorder with a mean age of onset of 40
years. The main clinical manifestations are chorea, cognitive
impairment, psychiatric disorders and weight loss. The disease
duration is 15–20 years and in the absence of disease modifying
treatments, the disease progresses inexorably until death [1]. The
mutation responsible for HD is an unstable expansion of a CAG
repeat in the HTT gene that leads to a polyglutamine expansion in
the N-terminus of the huntingtin (HTT) protein [2]. Neuropatho-
logically, HD is characterized by neuronal loss in several brain
regions including the striatum and the cortex as well as the
deposition of nuclear and cytoplasmic HTT-containing aggregates
[3].
A variety of mouse models have been used to study the
pathogenic pathways involved in HD [4]. These include the R6/2
model, which is transgenic for a single-copy of exon 1 of human
HTT, which in our colony carries approximately 200 CAG repeats
[5,6] and the HdhQ150 knock-in model in which 150 CAGs have
been inserted into the mouse Htt gene [7,8]. The R6/2 mouse has
an early onset progressive phenotype that recapitulates many
features of the human disease. Motor and cognitive impairment
appear before 6 weeks, HTT aggregation can clearly be detected
from 3 weeks, whereas neuronal cell loss in the striatum occurs at
later stages [9,10,11]. Mice with an average 200 CAG repeats are
not usually kept beyond 15 weeks. The early and reproducible
phenotype of this mouse line has made it an ideal model screening
compounds and performing genetic crosses. At late-stage disease,
the R6/2 and HdhQ150 models have developed remarkably
similar phenotypes [8,12,13,14] supporting the hypothesis that the
generation of a toxic fragment is a critical event in HD
pathogenesis [15].
In recent years, transcriptional dysregulation has emerged as a
pathogenic process that appears early in disease progression and
has been recapitulated across multiple HD model systems
including the R6/2 and HdhQ150 mouse models [12,16]. Histone
acetylation/deacetylation is an important mechanism involved in
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been proposed to underlie transcriptional dysregulation in HD
[17]. In general, acetylation of lysines by histone acetyl transferases
(HAT) leads to activation of transcription whereas removal of
acetyl groups by histone deacetylases (HDAC) leads to gene
silencing [18]. There are two evolutionary divergent types of
HDACs: the zinc-dependent HDACs (human HDAC1-11) and
the NAD
+ dependent HDACs also called sirtuins (human SIRT1-
7). Inhibitors of the zinc-dependant HDACs include suberoylani-
lide hydroxamic acid (SAHA) and trichostatin A (TSA) [19],
whereas sirtuins are inhibited by nicotinamide [20]. The human
zinc-dependent HDAC family comprises eleven members divided
into four classes: I (HDAC1, 2, 3 and 8), IIa (HDAC4, 5, 7 and 9),
IIb (HDAC6 and 10) and IV (HDAC11). HDAC inhibition has
been shown to improve polyglutamine-dependent phenotypes in
several models of HD [21,22,23,24,25,26]. Although administra-
tion of SAHA improves HD-related phenotypes in the R6/2
mouse model, therapeutic doses have toxic effects and induce
profound weight loss [24].
To better understand the mechanism underlying this potential
therapeutic benefit and to dissociate the beneficial and toxic effects
of SAHA, we set out to identify the specific HDAC(s) involved in
this process. For this purpose, we are exploring the effect of the
genetic reduction of specific HDACs on HD-related phenotypes in
R6/2 mice. Genetic reduction (knock-down or complete knock-
out) of Hdac5, 6, 7 and 9 failed to induce a phenotypic
improvement ([27,28] and unpublished data) whereas knock-
down of Hdac4 induces a significant beneficial effect (unpublished
data).
The study presented here focuses on HDAC3, which is the most
highly expressed class I HDAC in the brain [29]. This HDAC is of
particular interest for several reasons. Class I HDACs are directly
involved in histone deacetylation and as a class I HDAC, HDAC3
is one of the main cellular targets of SAHA [30]. A recent study
showed that the class I inhibitor HDACi 4b, which is reported to
be more specific for HDAC3 than the other class I HDACs,
ameliorated the disease phenotype and reversed many of the
transcriptional abnormalities found in the brain of R6/2 mice
[26]. Moreover, studies involving genetic reduction of specific
HDACs in invertebrate models of HD have implicated class I
HDACs in the reduction of polyglutamine-dependent toxicity. In
Drosophila melanosgaster, knock-down of the class I HDAC rpd3, that
is homologous to human HDAC1/2 but also partially homologous
to HDAC3, suppresses pathogenesis [31]. Similarly, in C. Elegans,
only the knock-down of the hda-3, that shares homology with
human class I HDACs, suppressed polyglutamine-dependant
toxicity [21]. Finally, the catalytic domain of HDAC4 interacts
with HDAC3 via the transcriptional corepressor complex N-CoR/
SMRT, and suppression of HDAC4 binding to SMRT/N-CoR
and to HDAC3 results in the loss of enzymatic activity associated
with HDAC4 [32]. Given the beneficial effect of Hdac4 knock-
down on HD-related phenotypes in R6/2 mice, we might expect
that a reduction of Hdac3 expression would lead a reduced
HDAC4 activity and an improvement in R6/2 phenotypes.
To evaluate a potential benefit of Hdac3 genetic reduction in
R6/2, we generated a genetically engineered mouse in which part
of the Hdac3 gene is deleted. We observed that a complete knock-
out of Hdac3 is embryonic lethal. Hdac3 mRNA levels were
reduced to 50% of wild type (WT) in the brains of Hdac3
+/2
heterozygotes (knock-down) with a corresponding reduction in
HDAC3 protein in the nucleus but not in the cytoplasm. We
found that Hdac3
+/2 heterozygotes are viable and fertile, with no
overt phenotype. We performed a genetic cross between R6/2
mice and Hdac3
+/2 heterozygotes and found that Hdac3 knock-
down does not ameliorate physiological or behavioural phenotypes
in R6/2 mice, does not modulate HTT aggregation and has no
effect on transcriptional dysregulation. We conclude that HDAC3
should not be considered as the major mediator of the beneficial
effect induced by SAHA and other HDAC inhibitors in HD.
Results
Conventional heterozygous deletion of Hdac3
We generated a conventional null allele of Hdac3 in order to
evaluate whether a reduction in HDAC3 level has beneficial
effects in the R6/2 mice. For this purpose, loxP sites were
introduced upstream of exon 11 and within exon 15 by
homologous recombination inducing a deletion covering exon 11
to 14 and the 59 end of exon 15 (Fig. 1A). This mutation removes a
part of the nuclear localization signal and a C-terminal region
necessary for both deacetylase activity and transcriptional
repression [33,34]. Heterozygous F1 mice were generated and
deletion of Hdac3 was confirmed at the genomic level by PCR and
sequencing (Fig. 1B). We intercrossed Hdac3
+/2 mice in order to
generate nullizygotes, but did not obtain any Hdac3 knock-out
offspring at birth or between embryonic stages E8.5 and E15.5.
This result reveals that a complete lack of Hdac3 induces an
embryonic lethality prior to E8.5 and confirms previous studies
showing that Hdac3
2/2 mice die before E9.5 [35,36]. Given this
embryonic lethality we used Hdac3
+/2 heterozygotes for our study.
These mice are viable and fertile, with no overt phenotype.
It was important first to confirm that the Hdac3 expression level
was reduced in Hdac3
+/2 mice as it has been previously shown that
Hdac1, another class I HDAC, autoregulates its expression to wild-
type (WT) levels in Hdac1
+/2 heterozygous mice [37]. It was also
important to determine whether Hdac3 levels might be regulated
by the R6/2 transprotein. Therefore, we crossed R6/2 males to
Hdac3
+/2 heterozygous females to generate WT, Hdac3
+/2, R6/2
and R6/2::Hdac3
+/2 double mutant (Dbl) mice and performed
RT-qPCR on cDNA prepared from cortex, cerebellum and
striatum of 15-week old mice. The RT-qPCR primer sequences
were located within the deletion (at the junction between exon 14
and 15) so that only the WT allele can be detected. We observed a
significant reduction of Hdac3 mRNA to 50% of the WT level in
all the brain regions irrespective of the presence of the R6/2
transprotein (Fig. 2A). In order to verify the specificity of Hdac3
reduction we analyzed the expression level of the other Hdacs by
RT-qPCR and showed that these were not changed in Hdac3
+/2
mice compared to WT (Fig. S1).
In order to see whether this mRNA reduction translates into a
reduction at the protein level, we performed western blotting on
whole brain lysates using an HDAC3 specific antibody. Surpris-
ingly, the protein level was only reduced to 80% of the WT level
(Fig. S2). As HDAC3 is present in both the nucleus and the
cytoplasm in mammalian cells [33], we investigated whether
HDAC3 levels might differ between these two intracellular
compartments. For this purpose, we performed nuclear and
cytoplasmic fractionation of whole brains from 4 week old mice.
We first confirmed that HDAC3 is present in both the nucleus and
cytoplasm in WT mouse brain (Fig. 2B). Analysis of brains from
WT, Hdac3
+/2, R6/2 and Dbl mice revealed that cytoplasmic
HDAC3 is not reduced in Hdac3
+/2 and Dbl brains as compared
to WT and R6/2. In contrast, its expression is reduced to 60% of
the WT level in Hdac3
+/2 heterozygotes irrespective of the
presence of the R6/2 transgene (Fig. 2C and D). As we are
primarily interested in the involvement of HDAC3 in transcrip-
tional repression through histone deacetylation, a specific
reduction of HDAC3 in the nucleus would be expected to be
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activity and explore its potential benefit in HD.
Genetic reduction of Hdac3 does not modify the R6/2
phenotype
A set of previously established quantitative tests was used to
evaluate whether a genetic reduction of Hdac3 had an effect on
HD-related phenotypes in R6/2 mice. In order to generate mice
for this analysis, R6/2 males were bred with Hdac3
+/2 females to
generate at least 12 mice per genotype (males and females, WT
n=16, Hdac3
+/2 n=14, R6/2 n=12, Dbl n=15). The mice were
born over a period of 5 days and the 4 genotypes were recovered
in a Mendelian ratio. The average CAG repeat size did not differ
between the R6/2 group and the Dbl group (20463.16 vs
20560.91; p=0.11). Body weight, RotaRod performance, grip
strength and exploratory activity were monitored from 4 to 15
weeks of age, and in each case, a specific test was performed by the
same operator, on the same day and at the same time during the
weeks in which measurements were taken.
Mice were weighed weekly from 4 to 15 weeks of age. As
expected, R6/2 mice weighed less overall than WT mice
[F(1,49)=32.657, p,0.001] and gained weight at a slower rate
[F(4,539)=38.086, p,0.001] (Fig. 3A). No significant differences in
the overall weight [F(1,49)=3.267, p=0.077] or in weight gain
Figure 1. Generation of an Hdac3 convention knock-out allele. (A) Strategy to generate an Hdac3 conventional knock-out allele. The genomic
structure and the targeting vector are shown. The Hdac3 gene contains 15 exons (blue rectangles). LoxP sites (red triangles) were introduced
upstream exon 11 and within exon 15. The vector contains a 59 homology arm covering the exonic and intronic region from intron 3–4 to intron 10–
11 and a 39 homology arm covering a part of exon 15 and the 39UTR (green rectangle). The conditional knock-out region (yellow rectangle) covers
exon 11 to 14 and 59 end of exon 15. This conditional allele was introduced by homologous recombination in ES cells. The neomycine cassette (pink
rectangle) flanked by 2 LoxP sites was removed by electroporation of Cre recombinase in ES cells and the cells containing the allele corresponding to
a complete deletion of exon 11 to 14 were selected. Primers used for genotyping are represented as black arrows. F1=forward 1; F2=forward 2;
R=Reverse. (B) Representative genotyping PCR on mouse genomic DNA. Duplex PCR with F1, F2 and R primers detects both the WT (250 bp band
with primers F2/R) and the knock-out (500 bp with primers F1/R) allele.
doi:10.1371/journal.pone.0031080.g001
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+/2 mice were
observed. However, there was a trend for Hdac3
+/2 mice to weigh
more than WT (p=0.077). Genetic reduction of Hdac3 had no
effect on R6/2 weight [F(1,49)=0.218, p=0.643] and did not
attenuate the rate of R6/2 weight loss [F(4,539)=1.458, p=0.222].
Therefore, genetic reduction of Hdac3
+/2 does not improve the
weight loss phenotype in the R6/2 mice.
RotaRod performance is a sensitive indicator of balance and
motor coordination, which has been reliably shown to decline in
R6/2 mice. RotaRod was assessed at 4, 8, 10, 12 and 14 weeks of
age. Consistent with previous data, R6/2 mice displayed a
significant decline in overall RotaRod performance [F(1,49)=
75.523, p,0.001] and this worsened with age [F(3,980)=23.764,
p,0.001] (Fig. 3B). Hdac3 knock-down had no effect on overall
RotaRod performance of Hdac3
+/2 mice [F(1,49)=0.386, p=
0.537] and did not significantly change the overall performance of
R6/2 mice [F(1,49)=0.478, p=0.493]. Furthermore, Hdac3 knock-
down had no effect on the deterioration of R6/2 RotaRod
performance with age [F(3,980)=0.344, p=0.792].
Forelimb grip strength was assessed at 4 weeks of age and then
weekly when the mice were 11 to 14 weeks old. Consistent with
previous data, R6/2 mice performance was significantly decreased
compared to WT [F(1,49)=105.705, p,0.001] and deteriorated
with age [F(3,392)=25.804, p,0.001] (Fig. 3C). The grip strength
Figure 2. Hdac3 mRNA and protein expression in Hdac3+/2 heterozygous mouse brain. (A) Hdac3 mRNA expression levels in 15 week old
mouse cortex, cerebellum and striatum are shown as a relative expression ratio to the WT level. Hdac3
+/2 (red) and Dbl (purple) mice express the
mRNA at 50% of the WT (blue) and R6/2 (green) levels in all brain regions. Error bars correspond to S.E.M. (n=8) ***p,0.001. (B) Western blot
showing the expression of HDAC3 protein in the cytoplasmic (C) and the nuclear (N) fraction of WT mouse whole brain. Antibodies to a-tubulin
(cytoplasmic) and histone H4 (nuclear) were used to control for the purity of the fractions. (C) Representative western blot and (D) quantification of
cytoplasmic and nuclear fraction prepared from WT (blue), Hdac3
+/2 (red), R6/2 (green) and Dbl (purple) 15 week old-mouse whole brains. Antibodies
to a-tubulin (cytoplasmic) and histone H4 (nuclear) were used as both purity and loading controls. Cytoplasmic HDAC3 was not affected by Hdac3
deletion whereas nuclear HDAC3 was reduced to 60% of the WT level. Error bars correspond S.E.M. (n=3) *p,0.05.
doi:10.1371/journal.pone.0031080.g002
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31080Figure 3. Hdac3 genetic reduction does not modify R6/2 phenotypes. (A) Weight loss in males (left panel) and females (right panel) are
shown between 4 and 15 weeks of age. Hdac3 genetic reduction did not induce a significant increase of the body weight in R6/2 (B) RotaRod
performance is represented as the average latency to fall in each group at 4, 8, 10, 12 and 14 weeks. Hdac3 genetic reduction did not ameliorate the
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+/2 mice was comparable to WT mice, both overall
[F(1,49)=0.230, p=0.634] and over the course of the experiment
[F(3,392)=0.675, p=0.586]. Furthermore, genetic reduction of
Hdac3 did not improve R6/2 overall grip strength performance
[F(1,49)=0.603, p=0.441] or deterioration with age [F(3,392)=
0.846, p=0.483].
Exploratory activity was assessed fortnightly from 5 to 13 weeks
of age as described previously and analyzed by repeated measures
general linear model (GLM) ANOVA. Mice were assessed for a
period of 30 min for total activity, rearing, centre rearing and
mobility. The p-values obtained for each parameter are displayed
in Table S1. For all genotypes, the mice are highly active and
mobile during the first part of the assessment period and this
decreased over the course of the 30 min (Fig. 3D and Fig. S3). R6/
2 mice show an overall hypoactivity and decreased mobility
relative to WT mice from 7 weeks onwards. Rearing and centre
rearing are also significantly decreased in R6/2 mice from 9 and
11 weeks of age respectively. Hdac3
+/2 mice were indistinguishable
from WT mice for all of the parameters. Furthermore, Hdac3
genetic reduction does not improve hypoactivity in the R6/2 mice.
Finally, we evaluated whether Hdac3 genetic reduction had an
effect on brain weight. Loss of brain weight has been observed in
R6/2 mice in previous studies [6]. Brains were harvested from
mice at 15 weeks of age, at the end of the trial. As expected, R6/2
mice displayed a significant decrease in brain weight
[F(1,49)=182.333, p,0.001] (Fig. 3E). ANOVA analysis failed to
detect any significant change in brain weight as a result of Hdac3
genetic reduction [F(1,49)=1.865, p=0.178]. Analysis of the results
by Student’s t-test revealed that Hdac3 knock-down induces a
significant increase in brain weight in the WT context (p=0.0074)
but no significant change was observed in the transgenic context
(Fig. 3E). The brain weight of the Dbl mice is not significantly
different from R6/2 (p=0.3857). This result suggests that Hdac3
knock-down has no effect on R6/2 mice brain weight loss.
Hdac3 genetic reduction does not ameliorate the
dysregulated expression of genes of interest in R6/2
mouse brains
HDAC inhibitors have been shown to reverse transcriptional
dysregulation in wide variety of HD models [17,26,38]. In order to
evaluate whether a genetic reduction of Hdac3 might modulate the
transcriptional changes observed in HD, we used RT-qPCR to
analyze the expression level of a set of ‘genes of interest’ in
different brain regions. This included cortical Bdnf as well as
cerebellar and striatal genes that are dysregulated in HD mouse
models [8,12]. This analysis was performed on brain regions taken
from 15 week old WT, Hdac3
+/2, R6/2 and Dbl mice. Changes in
gene expression induced by the transgene were consistent with
previous results for all the genes that were tested (Fig. 4A, B, C).
Genetic reduction of Hdac3 had no effect on the levels of the
dysregulated transcripts in R6/2 brain regions except for Bdnf V
(decreased expression, p=0.037) and Cnr1 (increased expression,
p=0.028) for which very mild but statistically significant changes
were observed in the cortex and in striatum respectively (Fig. 4A
and C). Similarly Hdac3 genetic reduction had no effect on the
expression of these genes in non-transgenic animals except for
Cnr1 for which a significant decrease in expression was observed in
Hdac3
+/2 compared to WT striata (p=0.012; Fig. 4C). We also
found that Hdac3 reduction does not affect the expression of the
R6/2 transgene in the cortex (Fig. 4D), cerebellum (Fig. 4E) and
striatum (Fig. 4F).
Hdac3 genetic reduction does not reduce Huntingtin
aggregation in R6/2 mouse brains
HTT aggregation is a hallmark of brain pathology in HD and
has been consistently observed in all HD models including the R6/
2 mouse. Aggregation can be detected in several R6/2 brain
regions from 3–4 weeks of age and increases with age [11]. In
order to evaluate whether Hdac3 reduction has an effect on this
aggregation, we used a SEPRION ligand-based ELISA that
provides a highly quantitative assay for measuring HTT
aggregation in mouse brains [14]. Aggregates were captured from
proteins extracted from the cortex, hippocampus and brain stem
of 4, 9 and 15 week-old mice and detected with the MW8 antibody
[39]. As expected, HTT aggregation was detectable at 4 weeks in
all three brain regions, increased with age and this was not
modified by Hdac3 reduction. Levels of soluble HTT in these
lysates can be quantified by western blot using the HTT specific
antibody S830 [40]. The soluble trans-protein migrates at around
95 kDa whereas the aggregated protein remains in the stacking
gel. Fig. 5B shows the results that we obtained for hippocampi
from mice of 4, 9 and 15 weeks of age. The soluble fraction
decreased with age in both R6/2 and Dbl mice and did not differ
significantly between these genotypes at any time point (Fig. 5C).
Similarly, a qualitative difference of the aggregated fraction was
not detected. Taken together, the data obtained from the ELISA
and western blotting revealed that Hdac3 genetic reduction has no
effect on HTT aggregation.
Discussion
HDAC inhibitors were first investigated as therapeutics in the
context of HD to counteract transcriptional dysregulation, thought
to contribute to the molecular pathogenesis of HD. They were first
shown to be protective in a Drosophila melanogaster model [25] and
following on from the demonstration that SAHA, a potent HDAC
inhibitor, improves HD-related phenotypes in the R6/2 mouse,
(Hockly et al., 2003), protective effects of the butyrates in HD
mouse models were also reported [22,23]. However, therapeutic
doses of SAHA were not well tolerated, leading to a marked
weight loss in both WT and R6/2 animal. Therefore, if HDAC
inhibitors are to be further developed as therapeutics for HD, it is
essential that efficacy can be uncoupled from toxicity as far as is
possible. As a pan-HDAC inhibitor, SAHA targets the eleven zinc-
dependant HDACs with a preference for class I HDACs (1, 2, 3
and 8) and the class IIb HDAC, HDAC6 [30]. Identifying more
specific inhibitors that target the HDAC(s) responsible for the
beneficial effects observed in HD mouse models might be one
mechanism by which the toxic effects could be diminished.
Toward this aim, we are systematically investigating the effects of
genetically reducing the levels of individual HDAC enzymes in the
R6/2 mouse. In this study, we focus on HDAC3 and show that the
impairment in RotaRod performance in R6/2 (C) Average grip strength in each group is represented at 4, 11, 12, 13 and 14 weeks. Hdac3 genetic
reduction did not induce a significant improvement in the grip strength in R6/2 mice (D) Average activity for each genotype is shown at 5 (upper
panel) and 13 (lower panel) weeks of age. Hdac3 genetic reduction did not reverse the hypoactivity observed in R6/2 mice (E) Average brain weight
for each group was measured at 15 weeks of age. Hdac3 genetic reduction did not modify the brain weight loss in R6/2 but a slight increase in brain
weight was observed in WT animals **p,0.01. Error bars correspond to SEM (n.12). The same color code (blue=WT; red=Hdac3; green=R6/2 and
purple=Dbl) was used for all measured parameters.
doi:10.1371/journal.pone.0031080.g003
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31080Figure 4. Hdac3 genetic reduction does not reverse transcriptional dysregulation in R6/2. (A) Expression of Bdnf transcripts from different
promoters (Bdnf I, IV and V) and the coding region (Bdnf B) in the cortex are represented as a percent of WT expression levels. With the exception of a
slight decrease in Bdnf V, Hdac3 reduction did not affect Bdnf expression. (B) Expression levels of genes specifically altered in the cerebellum of R6/2
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has no effect on HD-related behavioral and physiological
phenotypes or HTT aggregation. Importantly, the expression
levels of a specific set of dysregulated gene transcripts were not
restored.
HDAC3 was an interesting candidate for a number of reasons.
The specific HDACs involved in the therapeutic benefits observed
in invertebrate models of HD have also been explored by
systematic genetic invalidation-based studies. Although a direct
comparison with the mammalian enzymes cannot be made, as
there are only four HDACs in Drosophila melanogaster and eight in
Caenorhabditis elegans [21,31] both studies pointed to the class I
HDACs as being the critical mediators of the beneficial effects. In
Drosophila melanogaster, rpd3 knock-down suppressed neurodegener-
ation and extended the survival of transgenic flies [31]. Rpd3 is a
class I HDAC that shares amino-acid sequence similarities with
human HDAC1, 2 and 3 at 82%, 76% and 57% respectively. In
Caenorhabditis elegans, of the eight HDAC enzymes, it was only
knock-down of Hda-3 that induced a neuroprotective effect,
whereas knock-down of other HDACs, including the other class 1
orthologues Hda-1 and Hda-2, exacerbated toxicity [21]. However,
it was a pharmacological study in the R6/2 mouse model of HD
that indicated that HDAC3 rather than the other class I HDACs
might be the most relevant in a mammalian system. HDACi 4b is
one of a series of inhibitors for which the preferred cellular target
has been reported to be HDAC3 [41]. HDACi 4b was shown to
improve motor performance and body weight of R6/2 mice,
associated with a reversal of histone H3 hypoacetylation and the
correction of specific brain mRNA levels [26]. Given that we have
found that the genetic reduction of HDAC4 has beneficial effects
in the R6/2 mouse (unpublished data) and that the enzyme
activity of HDAC4 is dependent on its presence in the multi-
protein complex that contains HDAC3 and the SMRT/N-CoR
transcriptional repressors [32], HDAC3 was a therapeutic target
that merited further investigation.
Although HDAC3 is the most highly expressed HDAC in the
brain [29] little is known about its function in the central nervous
system. Specific silencing of Hdac3 in the hippocampus has been
shown to lead to long-term memory enhancement [42]. The
overexpression of Hdac3 in rat cerebellar neurons induces neuronal
death whereas suppression of its expression by shRNA protects
against low-potassium-induced neuronal death [43]. Unlike
HDAC1 and 2, which are predominantly nuclear proteins,
HDAC3 contains a nuclear export signal and is present in both
the nucleus and the cytoplasm in mammalian cells [33,44].
Investigations into the functions of the class I HDACs have been
confined to their roles in the nucleus: HDACs 1 and 2 are part of
the CoREST/mSin3a/NuRD repressor complex whereas
HDAC3 interacts with NCoR/SMRT to repress gene expression
[44], and in cortical neurons, HDAC3 is likely to be important for
SMRT nuclear retention [45]. We were surprised to find that the
cytoplasmic levels of HDAC3 in the brains of Hdac3
+/2
heterozygous mice were equivalent to that in WT brains, whereas
nuclear levels were reduced to approximately 60% of WT. The
fact that cytoplasmicHDAC3levelsaremaintainedintheHdac3
+/2
heterozygous state suggeststhat cytoplasmic HDAC3may be tightly
bound in a protein complex that sequesters HDAC3 and prevents it
from migrating to the nucleus.
Our inability to detect any beneficial consequences of reducing
nuclear HDAC3 levels in R6/2 mice was disappointing. The fact
that Hdac3
2/2 nullizygous mice die early in embryogenesis
indicates that another protein cannot compensate for HDAC3
function. We might expect that reduction of nuclear HDAC3 to
approximately 60% of WT levels could be similar to the level of
inhibition achieved by pharmacological approaches. Therefore,
the Hdac3
+/2 heterozygous mice present a suitable model with
which to further investigate the therapeutic potential of reducing
HDAC3 nuclear function. Our negative results would appear to
contradict the report that the administration of HDACi 4b to R6/
2 mice improves transcriptional dysregulation as well as behav-
ioural phenotypes [26]. However these previously reported
beneficial effects are surprising in the light of the physical stability
and metabolic issues concerning HDACi 4b that have recently
been highlighted (Beconi et al. unpublished data). Taken together,
the current data raise doubts as to the validation of HDAC3
inhibition as a therapeutic target for HD.
Materials and Methods
Generation of an Hdac3 null allele
The Hdac3-targeting vector was generated by PCR and
standard cloning. The 59 homology arm (4.7 kb), the 39 homology
arm (4.9 kb) and the knock-out region (4.5 kb) were generated by
PCR using high fidelity Prime Star HS DNA polymerase (Takara)
and RP23-24H23 BAC clone as a template. Aside from the
homologous arms, the final vector (HighQ1B-mHdac3) also
contains loxP sequences flanking the knock-out region (4.5 kb), a
neomycine resistance cassette (Neo, for positive selection of the ES
cells), and a diphtheria toxin gene cassette (DTA, for negative
selection of the ES cells). The targeting vector was linearized with
NotI and electroporated into C57BL/6NTac ES cells (an ES cell
line derived from C57BL/6 Taconic mice). The cells were selected
with 200 ug/ml G418 and 192 neo resistant ES clones were
screened for homologous recombination by Southern blot analysis.
Targeted ES cells were electroporated with the Cre-recombinase
and G418 sensitive clones were picked and analyzed by Southern
blot. Clones carrying a deletion of Exon 11 to 14 were identified
and microinjected into the blastocysts of C57BL/6 females to
generate chimeric mice. Chimeras were bred to C57BL/6 females
to achieve germ-line transmission and generate heterozygotes. The
deletion was confirmed at the genomic level by PCR and
sequencing.
Mouse maintenance and breeding
All animal work was approved by the King’s College London
Ethical Review Panel and experimental procedures were per-
formed in accordance with the UK Home Office regulations.
mice are represented as a percent of WT expression. No significant difference was induced by Hdac3 genetic reduction. (C) Expression levels of genes
specifically altered in the striatum of R6/2 mice are represented as a percent of WT expression. A significant decrease in the expression of Cnr1 in non-
transgenic animals was observed as well as a slightly significant increase in Cnr1 expression in R6/2 striata. Expression of the R6/2 transgene in Dbl
brains is represented as a percent of that in R6/2 brains for cortex (D), cerebellum (E) and striatum (F). Hdac3 reduction did not induce a significant
change in transgene expression. Error bars correspond to S.E.M. (n=8) *p,0.05. The same color code (blue=WT; red=Hdac3; green=R6/2 and
purple=Dbl) was used for all the graphs. Bdnf I, IV V, brain derived neurotrophic factor promoter I, IV, V; Bdnf B, brain derived neurotrophic factor
coding exon B; Igfbp5, insulin-like growth factor binding protein 5; Kcnk2, potassium channel subfamily K, member 2; Nr4a2, nuclear receptor
subfamily 4, group A, member 2; Pcp4, Purkinje cell protein 4; Uchl1, ubiquitin C-terminal hydrolase L1; Cnr1, cannabinoid receptor 1; Darpp32,
dopamine and cAMP regulated neuronal phosphoprotein; Drd2, dopamine D2 receptor; Penk1, proenkephalin.
doi:10.1371/journal.pone.0031080.g004
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backcrossing R6/2 males to (CBA6C57Bl/6) F1 (CBF) females
(B6CBAF1/OlaHsd, Harlan Olac). Hdac3
+/2 heterozygotes
originated in a C57Bl/6 background and were backcrossed once
to CBF females before breeding to R6/2 males. All animals had
unlimited access to water and breeding chow (Special Diet
Services, Witham, UK). Housing conditions and environmental
enrichment were used as previously described [46]. Hdac3
+/2
females were crossed to R6/2 males to generate WT, Hdac3
+/2,
R6/2 and Dbl mice. All cages contained at least one mouse of
each genotype and mice were additionally given mash that consist
of powdered chow mixed with water from 4 to 15 weeks. Mice
were subject to a 12 h light/12 h dark cycle.
Genotyping of R6/2 and Hdac3
+/2 mice and CAG repeat
sizing
R6/2 mice were genotyped by PCR of tail-tip genomic DNA.
PCR was performed using 16Thermo-start master mix (Thermo
scientific), 10% DMSO, 10 ng/ul forward primer 33727 (59-
CGCAGGCTAGGGCTGTCAATCATGCT-39), 10 ng/ul re-
Figure 5. Hdac3 genetic reduction does not reduce HTT aggregation in R6/2 mouse brain. (A) The SEPRION ligand based ELISA assay was
used to quantify HTT aggregation in the cortex, hippocampus and brain stem of 4, 9 and 15 week-old mice. The graphs represent the microtitre-plate
reading of R6/2 (green) and Dbl (purple) lysates. Background readings obtained with WT and Hdac3 lysates were comparable to water. Aggregation
levels augment with age but are not modified by Hdac3 reduction. Error bars correspond to S.E.M. (n.6). (B) Representative western blot of
hippocampal lysates at 4, 9 and 15 weeks of age. The aggregated HTT fraction (stacking gel) augments with age whereas the soluble fraction
decreases with age. a-tubulin was used as a loading control. (C) Quantification of (B). Soluble HTT is represented as a percentage of the soluble
fraction in R6/2. Error bars correspond to S.E.M. (n=6). The same color code (R6/2=green; Dbl=purple) is used in (A) and (C).
doi:10.1371/journal.pone.0031080.g005
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CAT-39) and 100 ng genomic DNA. Amplification conditions
were: 15 min at 94uC, 356 (30 s at 94uC; 30 s at 60uC; 60 s at
72uC), 10 min at 72uC. The amplicon for the R6/2 transgene is
272 bp. The CAG repeat size was determined as follow:
amplification of the CAG repeat from R6/2 mouse DNA was
performed with a FAM labelled forward primer (59-GA-
GTCCCTCAAGTCCTTCCAGCA-39) and reverse primer (59-
GCCCAAACTCACGGTCGGT-39) with 0.2 mM dNTPs; 10%
DMSO; AM buffer (67 mM TrisHCL pH 8.8; 16.6 mM (NH4)S04;
2m M M g C l 2; 0.17 mg/ml BSA) and 0.5 U AmpliTaq DNA
polymerase (Applied Biosystems). Amplification conditions were:
90 s at 94uC, 246(30 s at 94uC; 30 s at 65uC; 90 s at 72uC), 10 min
at 72uC. All instruments and materials were obtained from Applied
Biosystems unless indicated. The FAM-tagged PCR product (1 ul)
together with MegaBACETM ET900 (AmershamBioscience) inter-
nal size standard (0.04 ul) were denatured for 5 min at 94uCi n9u l
ofHiDi-formamide andanalysed using an ABI3730sequencer.Data
analysis was performed using platemanager application GeneMap-
per v5.2- 3730XL. Hdac3
+/2 mice were genotyped by duplex PCR
in a 10 ul reaction containing 100 ug gDNA, 2 ul of 56Promega
buffer, 1.2 ul of 25 mM MgCl2, 1 ul of 106 PCR Enhancer
(Invitrogen), 1 ul of 2 mM dNTP, 1 ul of 10 uM forward 1 (F1)
primer (59- GCTTAGCCTACTTGGCAAGTGCCAG-39), 1 ul of
10 uM forward 2 (F2) primer (59-GGCCAGAAGCACCCAAT-
GAGTTCTA-39), 1 ul of 10 uM reverse (R) primer (59- ACAAT-
CATCAGGCCGTGAGAGTTTG-39), 0.2 ul of Promega Taq
DNA polymerase and 4.4 ul H2O. Amplification conditions were:
10 min at 94uC, 406 (30 s at 94uC; 30 s at 58uC; 60 s at 72uC)
10 min at 72uC. The WT allele product is 250 bp and the Hdac3
knock-out allele is 500 bp.
Phenotypic analysis
The phenotypic analysis was performed on mice from 4 weeks
to 15 weeks of age (WT males n=9, females n=7; Hdac3
+/2
males n=7, females n=7; R6/2 males n=5, females n=7; Dbl
males n=10, females n=5). Mice were weaned 4 days before the
beginning of the analysis. Mice were weighed weekly to the nearest
0.1 g. Motor coordination was assessed using an Ugo Basile 7650
accelerating RotaRod with an acceleration set to run from 4 to 40
RPM in 300 seconds (Linton Instrumentation, UK). At 4 weeks of
age, mice were tested on four consecutive days, with three trials
per day. At 8, 10, 12 and 14 weeks of age, mice were tested on
three consecutive days with three trials per day. Forelimb grip
strength was measured once a week at 4 and from 11 to 14 weeks
using a San Diego Instruments Grip Strength Meter (San Diego,
CA, USA) as described in [24]. Exploratory spontaneous motor
activity was recorded and assessed fortnightly at 5, 7, 9, 11 and 13
weeks of age for 30 min during the day using infra-red activity
monitoring cages (Linton Instruments, AM1053) as described in
[47]. Briefly, activity (total number of beam breaks in the lower
level), mobility (at least two consecutive beam breaks in the lower
level) and rearing (number of rearing beam breaks) were
measured. The data were collected and analyzed as described in
[47]. At 15 weeks of age mice were sacrificed, brains were
extracted and weighed to the nearest 0.01 g.
RNA extraction and gene expression analysis
Brain regions were dissected, snap-frozen in liquid nitrogen and
stored at 280uC until required. Cortices, cerebella and striata
were homogenized in Qiazol reagent and extracted using Qiagen
RNeasy Mini kit (Qiagen). After quantification with a Nanodrop
1000 spectrophotometer (Labtech international), 1 ug of total
RNA was reverse transcribed in 20 ul RT reaction using MMLV-
RT kit (Invitrogen) and P21 random hexamers as described in
Benn et al, 2008. RT reaction was diluted 10 times in nuclease-
free Sigma water and 5 ul was used in 25 ul reaction containing
Precision MasterMix (PrimerDesign), 300 nM gene-specific prim-
ers and 200 nM fluorescent reporting probe (FAM labelled and
TAMRA quenched) specific to each target gene of interest using
the Opticon2 Real Time PCR detection system (MJ research).
Housekeeping genes previously identified [48] were used as ready-
mixed PerfectProbe sets containing primers and probe (PrimerDe-
sign). The geometric mean of three housekeeping genes for each
brain region (Atp5b, Canx, and Ubc for cortex; Atp5b, Eif4a2, and
Ubc for cerebellum, Atp5b, Ubc and Ywhaz for striatum) was used as
a reference in order to determine relative expression ratio of the
genes of interest using 2
2DDCt method. For Hdac3 expression
analysis, primers and probe were designed using Primer3 software
at the junction between exon 14 and 15 so only the WT allele can
be detected (forward primer 59- CGACGCTGAAGAGAGA-
GGTC -39, reverse primer 59- TTTCCTTGTCGTTGTC-
ATGG-39; probe 59- CCGAGGAGAACTACAGCAGG-39).
The amplicon was sequence-verified. For the other target genes,
primers and probes were used as in previous studies [28,48,49]
and their sequences are available in Table S2.
Isolation of nuclear and cytoplasmic fractions from
mouse brains
Brains were extracted from mice, snap-frozen in 250uC
isopenthane and stored at 280uC until required. All procedures
were performed on ice. Each brain was homogenized in 2 ml ice-
cold buffer 1 (575 mM sucrose; 25 mM KCl; 50 mM Trietha-
nolamine; 5 mM MgCl2; 5 mM DTT; 0.5 mM PMSF; 1 tablet
complete protease inhibitor cocktail from Roche) with 5–10
strokes in a 5 ml ice-cold homogenizer. The homogenate was then
centrifuged at 800 g for 15 min at 4uC. The supernatant
corresponds to the cytoplasmic fraction. The pellet was then
homogenized in 3 ml buffer 1 and 2 volumes (6 ml) of Buffer 2
(2.3 M sucrose; 24.8 mM KCl; 50 mM Triethanolamine; 5 mM
MgCl2; 1 mM DTT; 0.5 mM PMSF; 1 tablet complete protease
inhibitor cocktail from Roche) were added and mixed to the
homogenate. The mix was then centrifuged at 124000 g for
1 hour at 4uC (SW40 rotor in Beckman ultracentrifuge). The
pellet (nuclear fraction) was washed twice in Buffer 1 and finally
resuspended in 100 ul of Buffer 1.
Seprion ligand ELISA assay
Brain regions were dissected, snap-frozen in liquid nitrogen and
stored at 280uC until required. A 2.5% lysate was prepared by
ribolysing tissues for 3630 secin Lysing matrixtubes (Lysing matrix
D; MP Biomedicals) in ice-cold RIPA buffer (50 mM Tris-HCl
pH 8.0; 120 mM NaCl; 1% Igepal; 3.125% sodium deoxycholate;
0.01% SDS; 1 mM b-mercaptoethanol; 1 uM PMSF; 1 mM DTT;
1 tablet complete protease inhibitor cocktail from Roche). Lysates
werethen stored at 280uCandused within12 h.Fifteenmicroliters
of homogenate was mixed to 3 ul 10% SDS, 62 ul H2O and 20 ul
56capturebuffer(MicrosensBiotechnologies). Atotalof100 ulwas
transferred to the well of a Seprion ligand-coated ELISA plate, and
incubated with shaking for 1 h at room temperature (RT). The well
was then washed 56in PBS-T (PBS; 0.1% Tween) and incubated
shaking for 1 h at RT with 100 ul MW8 primary antibody (mouse
monoclonal antibody [39]) diluted 1:3000 in conjugate buffer
(150 mM NaCl; 4% BSA; 1% non-fat dried milk; 0.1% Tween 20
in PBS). After 5 washes with PBS-T, the well was incubated shaking
for 45 min at RT with 100 ul horse radish peroxidase (HRP)-
conjugated anti-mouse secondary antibody (DAKO) diluted 1:2000
in conjugate buffer. The well was then washed 56in PBS-T and
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the dark at RT for 5 min. Reactions were terminated by adding
100 ul 0.5 M HCl and the absorption at 450 nm was measured
using a plate reader (Biorad).
Western blotting and antibodies
The protein concentration of the whole brain cytoplasmic
fraction and RIPA extracted brain regions (ELISA) were
determined using the BCA assay kit (Thermo scientific). Twenty
micrograms of proteins were denatured in one volume of 26
sample buffer (125 mM Tris-HCl pH 6.8, 4% SDS, 20%
Glycerol, 10% b-mercaptoethanol, 0.004% bromophenol blue)
for 10 min at 95uC. Four microliters of the total 100 ul nuclear
fraction was also denatured in one volume of 26sample buffer for
10 min at 95uC. Lysates were then fractionated on 12% (nuclear
and cytoplasmic fraction) or 10% (RIPA-extracted protein lysates)
SDS-PAGE gels and electro-transferred into nitrocellulose mem-
branes (Whatman) by submerged transfer apparatus (Bio-Rad) in
(25 mM Tris, 192 mM glycine, 20% v/v methanol). Membranes
were blocked for 1 h at RT in 5% non-fat dried milk in PBS-T
(PBS; 0.2% Tween). Membranes containing nuclear and cyto-
plasmic fractions were then incubated with gentle agitation over
night at 4uC with an HDAC3 antibody (rabbit polyclonal Abcam,
1/1000) or 20 min RT with a mouse monoclonal a-tubulin
antibody (1/30000, Sigma) or rabbit polyclonal histone H4
antibody (1/5000, Millipore) in PBS-T, 5% non-fat dried milk.
Membranes containing RIPA-extracted protein lysates were
incubated 1 h RT with the sheep polyclonal S830 huntingtin
antibody [40] diluted 1:2000 in PBS-T, 5% non-fat dried milk or
a-tubulin antibody (20 min). For chemiluminescent detection,
membranes were washed 36in PBS-T probed with HRP-linked
secondary antibodies (HRP conjugated anti-rabbit mouse or sheep
antibody (1:10000, Dako) in PBS-T, 5% non-fat dried milk for
45 min at RT and washed 36in PBS-T. Protein was detected by
chemiluminescense (ECL reagent GE healthcare) according to the
manufacturer’s instructions. The signals were quantified using a
GS-800 calibrated densitometer (Bio-Rad).
Statistical analysis
Statistical analysis was performed by Student’s t-test (Excel or
SPSS), one-way ANOVA, two-way ANOVA and repeated
measures GLM ANOVA, with the Greenhouse–Geisser correc-
tion for non-sphericity using SPSS.
Supporting Information
Figure S1 Hdac3 genetic reduction does not affect the
expression of the other Hdacs. Expression of Hdac1-11
transcripts are represented as a percent of WT expression levels in
the cortex (A), the cerebellum (B) and the striatum (C) of 6 week
old WT and Hdac3
+/2 mice. The level of Hdac3 is the only
significant difference between WT and Hdac3
+/2 brain regions.
Error bars correspond to S.E.M. (n=6) ***p,0.001. The same
color code (blue=WT; red=Hdac3) was used for all the graphs.
(TIF)
Figure S2 HDAC3 protein expression in Hdac3+/2
heterozygous mouse brain. (A) Representative western blot
showing the expression of the HDAC3 protein in 4 week old
mouse whole brains extracted with RIPA buffer. a-tubulin was
used as a loading control (B) Quantification of (A). A slight
significant decrease (<20%) was induced by Hdac3 genetic
reduction. Error bars correspond to S.E.M. (n=3) *p,0.05.
Blue=WT; red=Hdac3.
(TIF)
Figure S3 Hdac3 genetic reduction does not modify R6/
2 exploratory activity. Average activity (left) rearing (middle)
and mobility (right) for each genotype is shown at 5, 7, 9, 11 and
13 weeks of age. The same color code (blue=WT; red=
Hdac3
+/2; green=R6/2 and purple=Dbl) was used for all the
graphs. R6/2 mice show an overall hypoactivity and decreased
mobility relative to WT mice from 7 weeks onwards and rearing is
significantly decreased in R6/2 mice from 9 weeks of age.
Hdac3
+/2 mice were indistinguishable from WT mice for all of the
parameters. Genetic reduction of Hdac3 failed to induce any
improvement for these parameters in R6/2 mice.
(TIF)
Table S1 Hdac3 genetic reduction does not modify R6/2
exploratory activity. The numbers displayed in Table S1
indicate the p-values for each of the parameters analysed (R6/2
genotype, Hdac3 genotype, time in the activity cages) at 5, 7, 9, 11
and 13 weeks of age. Significant p-values are highlighted in yellow
for p,0.05, orange for p,0.01 and pink for p,0.001. Mice in
activity cages are shown to behave differently with respect to
measures of exploratory behaviour (as determined by measuring
activity, mobility and rearing) over a period of 30 min (Time). R6/
2 mice exhibit an overall hypoactivity and a reduced mobility from
7 weeks and rearing is significantly reduced from 9 weeks (R6/2
genotype) and (Time*R6/2 genotype). Hdac3 genetic reduction
does not influence the behaviour of mice for any parameter
assessed (Hdac3 genotype) and (Time*Hdac3 genotype) and
furthermore, there appears to be no interaction between Hdac3
and R6/2 genotypes (R6/2*Hdac3) and (R6/2*Hdac3*time).
(DOCX)
Table S2 Sequences of primers and Taqman probes
used in real-time PCR assays. Bdnf I, IV V, brain derived
neurotrophic factor promoter I, IV, V; Bdnf B, brain derived
neurotrophic factor coding exon B; Cnr1, cannabinoid receptor 1;
Darpp32, dopamine and cAMP regulated neuronal phosphopro-
tein; Drd2, dopamine D2 receptor; Hdac1-11, histone deacetylase
1–11; Htt, huntingtin gene; Igfbp5, insulin-like growth factor
binding protein 5; Kcnk2, potassium channel subfamily K, member
2; Nr4a2, nuclear receptor subfamily 4, group A, member 2; Pcp4,
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